US EditionPublished • loading... • Updated
Imbed Biosciences Secures Strategic Investment from BioLab Holdings
BioLab Holdings invests to broaden Imbed Biosciences' wound care reach in U.S. MD offices using proprietary antimicrobial technology to reduce complications, CEO said.
- In a PR Newswire release today, Imbed Biosciences announced a strategic investment from BioLab Holdings, Inc., a Phoenix-based wound‑protection manufacturer.
- BioLab said the funding will significantly expand Imbed's reach within the U.S., especially in MD/physician office settings, and accelerate commercialization to minimize wound-care complications.
- Imbed's platform integrates multiple therapeutic agents into ultra-thin, biocompatible matrices to support skin regeneration and reduce infection risk, pain, and promote healing for patients and clinicians in MD/physician office settings.
- Microlyte, Imbed's lead product, targets chronic wounds, and BioLab said funding will support U.S. market expansion and market adoption efforts for Imbed.
- Contrasted with 'Lite' and 'Membrane Wrap', Imbed holds a unique position as the only fully synthetic, antimicrobial skin substitute, aligning with BioLab's mission, said BioLab.
Insights by Ground AI
14 Articles
14 Articles
Imbed Biosciences Secures Strategic Investment from BioLab Holdings
MIDDLETON, Wis., Feb. 3, 2026 /PRNewswire/ -- Imbed Biosciences, a leader in advanced synthetic antimicrobial and tissue regeneration solutions, today announced a strategic investment from BioLab Holdings Inc. This investment is set to significantly expand Imbed Biosciences' reach within the…
Coverage Details
Total News Sources14
Leaning Left0Leaning Right0Center7Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
